Our People

About Us Navigation

Dr Cathy Tralau-Stewart - Head of The Drug Discovery Centre
Dr Albert Jaxa-Chamiec - Head of Medicinal Chemistry
Dr Caroline Low - Head of Molecular Modelling/CADD
Dr Hayley Cordingley - Project Manager
Dr Katie Chapman - Senior Assay Development Scientist

Cathy Tralau-Stewart PhD

Head of Drug Discovery Facility & Pharmacology

Email: c.tralau@imperial.ac.uk
 Tel: +44 (0)20 331 10179

Cathy completed her PhD in Clinical Science (Oncology) at University College London in 1989. She has over 20 years experience of drug discovery within GlaxoSmithKline ranging from target validation, through lead optimisation, candidate characterisation and phase I to IV clinical trials. She has been involved in leading project teams which identified of over 20 development compound candidates in a range of therapeutic areas and with the discovery / development of Zantac, Seretide, Serevent, Flonase, Flovent, Allermist, Veramyst, Mepolizumab, Ariflo, Avodart,, Darotropium.

Albert Jaxa-Chamiec PhD

Head of Medicinal Chemistry

Email: a.jaxa-chamiec@imperial.ac.uk
Tel: +44 (0)20 331 10177

Albert Jaxa-Chamiec has many years of industrial experience in the field of Medicinal Chemistry. Before joining Imperial College in 2007, he was Head of Medicinal Chemistry 2 in GlaxoSmithKline, Psychiatry CEDD where he was working in the field of schizophrenia and bipolar disorder targets; NGAA, NK3, GlyT-1 inhibitors, selective M1agonists, AMPA modulators, use-dependent Na channel blockers, a7 positive modulators, mGluR5 positive modulators, D4 agonists.

Caroline Low PhD

Head of Molecular Modelling & Computer-Aided Drug Design

Email: c.low@imperial.ac.uk 
Tel: +44 (0)20 331 10176

Caroline Low gained her PhD in Organic Chemistry from Imperial before she began her career as a medicinal chemist working for Sir James Black OM, FRS, Nobel Laureate. She later took responsibility for the molecular modeling effort at the James Black Foundation, working closely with Dr. Andy Vinter to develop a “field point” approach to design new compounds for G-protein coupled receptor targets. Four of these compounds were taken into clinical trials for cancer by Johnson & Johnson.

Hayley Cordingley PhD

Project manager

Email: h.cordingley@imperial.ac.uk
Tel: +44 (0)20 331 10178

Hayley Cordingley joined Imperial in February 2007 following 10 years of working at GlaxoSmithKline which she joined following her PhD in Cellular Biology gained from the NIMR. During her career she has worked in a variety of fields including the development of novel technologies for improved drug screening (with special interest in microfluidics), the use of proteomics for toxicity prediction, and the study of cellular adhesion molecules. She has worked on a number of multi-party academic:industrial collaborations and currently acts both as a project manager and cellular biologist for the Drug Discovery Centre.

Katie Chapman PhD

Senior Assay Development Scientist

Email: kchapman@imperial.ac.uk
Tel: +44 (0)20 331 10178

Katie completed her PhD at Leeds University 2006, where she worked on the structural and functional relationship of the GPCR, Melanocortin 4 receptor. After Leeds she worked at GSK and was involved in screening and compound profiling on a number of targets across GPCR, Enzymes and Kinase arena with experience of developing native tissue systems. She has worked on a number of programs within Neuroscience before coming to Imperial College in 2010.